

REMARKS

Claims 27-42 have been canceled without prejudice or disclaimer. Claims 43-61 have been added and therefore are pending in the present application. Claims 43-61 are supported by claims 1-26. The N-terminal amino acid recited in claim 43 is supported by Example 2 at page 32, lines 35-36 of the specification.


Applicants enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same. The specification has been amended to correct the sequence identifiers. In addition, the specification has been amended to correct the N-terminal sequence recited at page 32, lines 35-36, as supported by the originally-filed sequence listing. This submission contains no new matter.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance.

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: January 31, 2003


Elias J. Lampiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 5843.200-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Schülein et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Sir:

Below is a marked-up version of the amendments made in the accompanying amendment.

IN THE SPECIFICATION:

Please replace the paragraph on page 27, lines 6-9 with:

The two PCR primers used have the following sequences:

LWN5494 5'-GTCGCCGGGGCGGCCGCTATCAATTGGTAACTGTATCTCAGC -3' (SEQ ID NO: 34)

LWN5495 5'-GTCGCCCGGGAGCTCTGATCAGGTACCAAGCTTGTCGACCTGCAGAA
TGAGGCAGCAAGAAGAT -3' (SEQ ID NO: 42)

Please replace the paragraph on page 27, lines 16-32 with:

This cloning replaces the first amyL promoter cloning with the same promoter but in the opposite direction. The two primers used for PCR amplification have the following sequences:

#LWN5938 5'-GTCGGCGGCCGCTGATCACGTACCAAGCTTGTCGACCTGCAGAATG
AGGCAGCAAGAAGAT -3' (SEQ ID NO: 53)

#LWN5939 5'-GTCGGAGCTCTATCAATTGGTAACTGTATCTCAGC -3' (SEQ ID NO: 64)

The plasmid pSJ2670 was digested with the restriction enzymes PstI and BclI and a PCR fragment amplified from a cloned DNA sequence encoding the alkaline amylase SP722 (disclosed in the International Patent Application published as WO 95/26397 which is hereby incorporated by

RECEIVED
FEB 12 2003
TO 100 MAIL ROOM

reference in its entirety) was digested with PstI and BclI and inserted to give the plasmid pMOL944. The two primers used for PCR amplification have the following sequence:

#LWN7864 5' -AACAGCTGATCACGACTGATCTTTTAGCTTGGCAC-3' (SEQ ID NO: 75)

#LWN7901 5' -AACTGCAGCCGCGGCACATCATAATGGGACAAATGGG -3' (SEQ ID NO: 86)

Please replace the paragraph on page 30, lines 9-13 with:

Cel9.B.lich.upper.PstI

5'-CAT CAT TCT GCA GCC GCG GCA GCT TCT GCT GAA GAA TAT CCT C-3' (SEQ ID NO: 97)

Cel9.B.lich.lower.NotI

5'-GCG AGA ATA GCG GCC GCT AGT AAC CGG GCT CAT GTC CG-3' (SEQ ID NO: 108)

The paragraph on page 32, lines 35-36 has been amended as follows:

N-terminal determination of the pure endoglucanase: EYPHNYAELLQK (amino acids 1-12 of SEQ ID NO: 2).